In search for therapies for solid tumors, companies turn to claudin

MollyFergusonforSTATOnTargetisarecurringfeaturefromSTATthatdivesdeepintothemostpromisingdrugtargetsi ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN




entertainment

author：focus    Page View：8
The Roche booth at ESMO in Madrid.
Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

advertisement

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Flu vaccine offering decent levels of protection this winter, new data show
Next article： Guidelines to prevent youth baseball injuries need more muscle